Global Acromegaly - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035

Global Acromegaly Market Outlook

Thelansis's "Global Acromegaly Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acromegaly treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Acromegaly Overview

Acromegaly is an insidious, debilitating endocrine disorder characterized by progressive somatic overgrowth driven by chronic growth hormone (GH) hypersecretion-typically from a benign pituitary adenoma-and the subsequent elevation of insulin-like growth factor 1 (IGF-1). Because onset is subtle, diagnosis is notoriously delayed by 4 to 10 years. Patients classically develop distinctly enlarged, spade-like hands and feet, profound facial distortion, and life-threatening systemic morbidities, including severe cardiovascular disease and type 2 diabetes. The primary therapeutic standard is endoscopic transsphenoidal surgical resection to remove the tumor and achieve prompt biochemical cure. For persistent disease, targeted medical management-utilizing somatostatin receptor ligands (SRLs) and GH receptor antagonists-is definitively required to normalize IGF-1 levels, halt tissue proliferation, and mitigate the risk of premature mortality.

Key Highlights

• In Germany, prevalent acromegaly cases are projected to increase from approximately 6,726 in 2025 to 7,022 by 2035.
• Acromegaly is a rare endocrine disorder caused primarily by growth hormone-secreting pituitary adenomas.
• Delayed diagnosis remains a major challenge due to the gradual onset of symptoms.
• Long-term complications include cardiovascular disease, metabolic disorders, and reduced quality of life.
• Advances in medical therapies and disease monitoring are improving disease control rates.

Market Overview

• The France acromegaly market is projected to grow from approximately $420 MN to $630 MN by 2035.
• Market growth is supported by:
• Increasing utilization of somatostatin analogs and targeted therapies
• Improved long-term management of chronic disease
• Market value growth is driven by prolonged treatment duration and premium biologic therapies.
• Future growth will depend on next-generation endocrine therapies and personalized treatment strategies.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Alexion Pharmaceuticals, Inc.
• Crinetics Pharmaceuticals Inc.
• Camurus AB
• Debiopharm International SA
• Marea Therapeutics
• Immunwork, Inc.